Stiripentol for primary hyperoxaluria types 1, 2, or 3
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether stiripentol can lower oxalate levels in people with primary hyperoxaluria, a rare condition that causes kidney stones and can lead to kidney damage. It may help reduce the risk of kidney failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 6 years old.
- You must have a confirmed diagnosis of primary hyperoxaluria type 1, 2, or 3.
- Your kidney function must be at least 45 mL/min/1.73m² (your doctor can check this).
- You must be on standard treatments (like drinking more fluids, vitamin B6, or potassium citrate) and, if taking lumasiran, you must have been on it for at least 6 months with no recent dose changes.
- If you are a female who can have children, you must use effective birth control and have a negative pregnancy test before starting.
- You must not have had a kidney or liver transplant, and your liver function tests must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This trial tests an experimental oral medicine called TRA16 for people with enteric hyperoxaluria—a condition where the gut absorbs too much oxalate, leading to high levels in the urine and raising the risk of kidney stones. The goal is to see if the drug safely reduces urine oxalate levels.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Hear when a new Primary Hyperoxaluria Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.